http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106008591-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2015-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106008591-B |
| titleOfInvention | A kind of synthesis of complex, sign and active anticancer assay method |
| abstract | The present invention relates to a kind of complex, its chemical formula is [VO 2 (tpy)]ClO 4 , the compound have anti-cancer herb activity and be expected to turn into the efficient cancer therapy drug of low toxicity, the complex [VO 2 (tpy)]ClO 4 Synthesis include [VO 2 (tpy)]ClO 4 Monocrystalline is synthesized and [VO 2 (tpy)]ClO 4 Crystallite or powder synthesis, with unique active anticancer, especially have especially strong lethality, its IC to liver cancer cells BEL 7402 50 =0.4 ± 0.2 μM, and conventional anti-cancer medicines cis-platinum is under identical condition, to the IC of the cells of BEL 7402 50 It is worth for 11.5 ± 1.3 μM, the resisting liver cancer activity of the complex is nearly 30 times of cis-platinum, can reaches that the medicine of such active anticancer is also very rare at present, this is that the property of the multiple oxidation states by the unique structure of complex and v element is closely related, due to IC 50 0.3 μM of the concentration that value is allowed close to human body, such compound is simultaneously expected to exploitation for new low toxicity, efficient cancer therapy drug. |
| priorityDate | 2015-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.